Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2025-12-25 @ 7:36 PM
Study NCT ID:
NCT07265232
Status:
RECRUITING
Last Update Posted:
2025-12-04
First Post:
2025-11-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
Sponsor:
Lantu Biopharma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-15
Start Date Type:
ACTUAL
Primary Completion Date:
2030-10-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-10-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-21
First Submit QC Date:
None
Study First Post Date:
2025-12-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-04
Last Update Post Date Type:
ESTIMATED